Abstract
Although several liver diseases of childhood, particularly biliary atresia(BA) and cystic fibrosis (CF) liver disease (CFLD) are characterized by hepatic fibrosis, the pathogenesis of this process is incompletely understood. The cytokine transforming growth factor-β1 (TGF-β1) has been implicated in hepatic fibrosis in experimental animals, in which both the hepatic expression and plasma concentration of this cytokine are increased. The objective of our study was to determine whether there are similar alterations of TGF-β1 in patients with hepatic fibrosis secondary to either BA and/or CFLD. The study design was as follows. In study 1, plasma TGF-β1 was assessed by ELISA in 9 children with BA undergoing liver transplantation, 11 patients with CFLD, and appropriate control subjects. In study 2, hepatic expression of TGF-β1 protein (assessed immunohistochemically) and hepatic fibrosis were scored semiquantitatively, on a 1-3 scale, by blinded investigators, in archival liver biopsy specimens from 10 children with BA, 10 with CFLD, and from 10 older children with normal hepatic histology, as well as in 4 patients with liver diseases of various etiologies. Simultaneous plasma and liver TGF-β1 studies were performed in 8 patients with liver disease. Results were as follows. Plasma TGF-β1 values were inversely correlated with age in healthy subjects(r = -0.54, p < 0.0001). The plasma TGF-β1 protein of children with BA was decreased (13 ± 2 ng/mL) compared with values for healthy children (42 ± 6 ng/mL, n = 10,p < 0.005). Similarly, the plasma TGF-β1 concentration in patients with CFLD was also decreased compared with values for children with CF and normal serum liver profiles (n = 14) (2 ± 1 ng/mL versus 12 ± 1, p < 0.05). However, the plasma TGF-β1 concentration was increased in two patients with other types of liver disease. The hepatic expression of TGF-β1 was increased in the presence of hepatic fibrosis in all types of liver diseases studied. Forty-six percent of patients had both marked hepatic fibrosis and marked TGF-β1 labeling; 86% of samples without fibrosis showed no TGF-β1 labeling, p = 0.007. In conclusion, these studies have established the association of hepatic TGF-β1 protein and hepatic fibrosis in several common liver diseases of childhood. Our data also suggest that, in children, plasma TGF-β1 does not appear to be a useful marker of hepatic expression of this cytokine.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- BA:
-
biliary atresia
- CF:
-
cystic fibrosis
- CFLD:
-
cystic fibrosis liver disease
- TGF-β1:
-
transforming growth factor-β1
- ALT:
-
alanine aminotransferase
- TBS:
-
Tris-buffered saline
- PF4:
-
platelet factor 4
- AST:
-
aspartate aminotransferese
References
Stein JE, Vacanti JP 1994 Biliary atresia and other disorders of the extrahepatic biliary tree. In: Suchy F (ed) Liver Disease in Children, 1st Ed. Mosby-Yearbook, St. Louis, pp 426–429.
Gaskin K 1994 The liver and biliary tract in cystic fibrosis. In: Suchy F (ed) Liver Disease in Children, 1st Ed. Mosby-Yearbook, St. Louis, pp 712–714.
M Border WA, Noble NA 1994 Transforming growth βfactor in tissue fibrosis. N Engl J Med 331: 1286–1292.
Armendariz-Borunda J, Katai H, Jones CM, Seyer JM, Kang AH, Raghow R 1993 Transforming growth factor β gene expression is transiently enhanced at a critical stage during liver regeneration after CC14 treatment. Lab Invest 69: 283–294.
Czaja MJ, Weiner FR, Flanders KC, Giambrone MA, Wind R, Biempica L, Zern MA 1989 In vitro and in vivo association of transforming growth factor-1 with hepatic fibrosis. J Cell Biol 108: 2477–2482.
Frizell E, Abraham A, Doolittle M, Bashey R, Kresina T, Van Thiel D, Zern MA 1994 FK506 enhances fibrogenesis in vitro and in vivo models of liver fibrosis in rats. Gastroenterology 107: 492–498.
Parola M, Muraca R, Dianzani I, Barrera G, Leonarduzzi G, Bendinelli P, Piccoletti R, Poli G 1992 Vitamin E dietary supplementation inhibits transforming growth factor beta 1 gene expression in the rat liver. FEBS Lett 308: 267–270.
Krull NB, Zimmermann T, Gressner AM 1993 Spatial and temporal patterns of gene expression for the proteoglycans biglycan and decorin and for transforming growth factor-β1 revealed by in situ hybridization during experimentally induced liver fibrosis in the rat. Hepatology 18: 581–589.
Kresina TF, He Q, Degli Esposti S, Zern MA 1994 Gene expression of transforming growth factor β1 and extracellular matrix proteins in murine Schistosoma mansoni infection. Gastroenterology 107: 773–780.
Saperstein LA, Jirtle RL, Farouk M, Thompson HJ, Chung KS, Meyers WC 1994 Transforming growth factor β1 and mannose 6-phosphate/insulin-like growth factor-II receptor expression during intrahepatic bile duct hyperplasia and biliary fibrosis in the rat. Hepatology 19: 412–417.
Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, Roberts AB, Sporn MB, Thorgeirsson SS 1995 Hepatic expression of mature transforming growth factor β1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 92: 2572–2576.
Nagy P, Scjaff Z, Laois K 1991 Immunohistochemical detection of transforming growth factor β1 in fibrotic liver diseases. Hepatology 14: 269–273.
Malizia G, Brunt EM, Peters MG, Rizzo A, Broekelmann TJ, McDonald JA 1995 Growth factor and procollagen type I gene expression in human liver disease. Gastroenterology 108: 145–156.
Castilla A, Prieto J, Fausto N 1991 Transforming growth factor 1 and in chronic liver disease: effects of interferon alfa therapy. N Engl J Med 324: 933–940.
Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, Kiso S, Matsuzawa Y 1994 Plasma transforming growth factorβ1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 73: 2275–2279.
Danielpour D 1993 Improved sandwich enzyme-linked immunosorbent assays for transforming growth factor β1. J Immunol Methods 158: 17–25.
Flanders KC, Tompson NL, Cissel DS, Van Oberghen-Schilling E, Baker CC, Kass ME, Ellingsworth LR, Roberts Ab, Sprorn MB 1989 Transforming growth factor β1: histochemical localization with antibodies to different epitopes. J Cell Biol 108: 653–660
Laffi G, Marra F, Gresele P, Romagnoli P, Palermo A, Bartolini O, Simoni A, Orlandi L, Selli ML, Menci GG 1992 Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. Gastroenterology 103: 641–646.
Acknowledgements
The authors thank Drs. Lalage Wakefield and Michael Sporn for their advice regarding the TGF-β1 analyses, Drs. Beryl Rosenstein, Alan Lake, and Paul Colombani for patient referrals, Drs. Harold Lehmann and Raphael Viscidi for assistance with data analysis, Dr. Stephen J. Qualman for contributing tissue specimens, and Margaret Wilson for secretarial support.
Author information
Authors and Affiliations
Additional information
Supported in part by the Cystic Fibrosis Foundation's Clinical Fellowship Award and Student Traineeship Award.
Rights and permissions
About this article
Cite this article
Rosensweig, J., Omori, M., Page, K. et al. Transforming Growth Factor-β1 in Plasma and Liver of Children with Liver Disease. Pediatr Res 44, 402–409 (1998). https://doi.org/10.1203/00006450-199809000-00023
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/00006450-199809000-00023
